Aim To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID pandemic. Methods IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and nucleoprotein, were used. Results Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive) as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively. Conclusion The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.
【저자키워드】 COVID-19, SARS-CoV-2, IgG, IgM, Diagnosis, IgA, 【초록키워드】 pandemic, Hospitalization, antibody, multicenter study, hospital, diagnostic test, Spike protein, COVID, sensitivity, Viral, PCR, Serological assay, IgG antibodies, serological assays, diagnostic tests, Spain, Clinical management, multicenter, nucleoprotein, PCR test, serological response, COVID-19 patient, IgG and IgM, Support, viral spike protein, positive, ELISA kit, IgA responses, IgA response, Spanish, first positive, Result, evaluate, the patient, evaluated, were used, were measured, 【제목키워드】 hospital, Patient, multicenter,